All In Biotech

Drug Trial Radar · NCT07693751

A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

A First-in-human Phase 1/2 Trial to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Aug 12, 2026

Primary completion

Nov 29, 2027

Study completion Jul 4, 2028

Sponsor

Lead sponsor
SOTIO Biotech a.s.Industry
Sponsor type
Industry
First posted
Jul 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SOT109 is a special cancer medicine designed to find and kill certain cancer cells that carry a marker called CDH17, while causing less harm to healthy cells. The study consists of two parts, Part A and Part B. The goal of Part A is to collect information about SOT109, understand its effects, and see whether it is safe and well tolerated at different dose levels. Part B of the study collects information on which of the two selected safe dose levels chosen in Part A gives the best balance between benefit and risk.

Conditions

  • Colorectal Cancer (Locally Advanced or Metastatic)

Interventions

  • SOT109Biological

    SOT109 is a CDH17-directed monoclonal antibody conjugated to a linker-payload, exatecan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of SOT109Time frame: At the end of Cycle 1 (one cycle is 21 days)
  2. Part B: Optimal dose of SOT109 for subsequent clinical trialsTime frame: Cycle 1 Day 1 up to 30 days after the last dose (each cycle is 21 days)
  3. Part B: Objective Response Rate (ORR) of SOT109Time frame: From Day 1 of Cycle 1 (one cycle is 21 days) until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, to be assessed up to approximately 9 months
  4. Part B: Duration of Response (DoR) of SOT109Time frame: From the date of first documented objective response until disease progression, initiation of new anticancer therapy, withdrawal of consent, or study discontinuation, whichever comes first, assessed up to approximately 9 months.

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • NEXT Houston

    Houston, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Masarykův onkologický ústav

    Brno, Czechia · Recruiting

  • Arensia Exploratory Medicine Research Unit, Institute of Oncology

    Chisinau, Moldova · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.